Naoya Kato
Chiba University
VirologyHepatitisHepatitis C virusDiabetes mellitusMedicine
What is this?
Publications 75
#1Yushi Imai (Chiba University)
#2Tetsuhiro Chiba (Chiba University)H-Index: 30
Last. Tomoko Saito (Chiba University)H-Index: 11
view all 21 authors...
#1KeiichiFujiwara (Chiba Prefectural University of Health Sciences)H-Index: 23
#2Nobuaki Nakayama (Saitama Medical University)H-Index: 15
Last. Satoshi Mochida (Saitama Medical University)H-Index: 31
view all 7 authors...
Background The prognosis of autoimmune acute liver failure (ALF) without liver transplantation (LT) is poor worldwide. We subanalyzed infectious complications of autoimmune ALF using data of nationwide surveys between 2010 and 2015 retrospectively and tried to determine when to evaluate the efficacy of corticosteroid (CS) treatment or abandon it for LT based on objective data. Methods One hundred and forty-four patients with autoimmune ALF, comprising 79 ALF with coma ≤ I, 52 ALF with coma ≥ II ...
#1Kenichiro Okimoto (Chiba University)H-Index: 10
#2Daisuke Maruoka (Chiba University)H-Index: 13
Last. Naoki Akizue (Chiba University)H-Index: 1
view all 14 authors...
#1Hirotaka Oura (Chiba University)
#2Tomoaki Matsumura (Chiba University)H-Index: 15
Last. Kenichiro Okimoto (Chiba University)H-Index: 10
view all 16 authors...
#1Hang Viet Dao (Chiba University)
#2Tomoaki Matsumura (Chiba University)H-Index: 15
Last. Mai Fujie (Chiba University)H-Index: 3
view all 17 authors...
: Ineffective esophageal motility (IEM) is the most common manometric abnormality in gastroesophageal reflux disease (GERD). However, the impact of IEM on esophageal chemical clearance has not been fully investigated. This study aimed to determine the impact of IEM on esophageal chemical clearance in patients with GERD. A total of 369 patients with GERD symptoms who underwent upper endoscopy and high-resolution manometry (HRM) test were retrospectively analyzed. The relationship between IEM and ...
#1Sadahisa Ogasawara (Chiba University)H-Index: 18
#2Yoshihiko Ooka (Chiba University)H-Index: 16
Last. Naoya Kato (Chiba University)H-Index: 13
view all 3 authors...
Lenvatinib is an oral molecular target agent that blocks vascular endothelial growth factor receptors 1–3, fibroblast growth factor receptors 1–4, platelet-derived growth factor receptor α, RET , and KIT . It is noninferior, but not statistically superior, to sorafenib with regard to overall survival, according to the findings of a phase 3 trial of lenvatinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma (HCC) (the REFLECT trial) (1). Nowadays, lenvatinib has been ...
#1Kengo Kanayama (Chiba University)H-Index: 2
#2Tetsuhiro Chiba (Chiba University)H-Index: 30
Last. Masato NakamuraH-Index: 32
view all 19 authors...
: Aim: Tolvaptan, an oral vasopressin-2 antagonist, sometimes improves hepatic edema including ascites in patients with decompensated cirrhosis. In this study, we examined the effectiveness and survival advantage in patients with the long-term administration of tolvaptan. Methods: A total of 115 patients with refractory ascites who were treated with tolvaptan were retrospectively analyzed based on their clinical records. Patients with a decrease in body weight of ≥1.5 kg from the baseline on day...
#1Shigeo Yasuda (NIRS: National Institute of Radiological Sciences)H-Index: 19
#2Hirotoshi KatoH-Index: 20
Last. Masaru Miyazaki (International University of Health and Welfare)H-Index: 33
view all 31 authors...
Abstract Purpose Carbon ion beams have several physical and biological advantages compared with conventional radiation for cancer therapy. The objective of this study is to evaluate the safety and effectiveness of two-fraction carbon ion radiotherapy (CIRT) in patients with hepatocellular carcinoma (HCC). Methods and Materials Between December 2008 and March 2013, 57 patients with localized HCC were treated with CIRT at a total dose of 45 Gy (RBE) in two fractions and retrospectively analyzed af...
#1MasatoshiKudo (Kindai University)H-Index: 78
#2Masafumi IkedaH-Index: 36
Last. Takeyuki IwataH-Index: 1
view all 12 authors...
513Background: LEN, a multikinase inhibitor of VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT with immunomodulatory activity, is approved in multiple countries for first-line treatment of uHCC. NIV is a...
1 CitationsSource
#1Sadahisa Ogasawara (Chiba University)H-Index: 18
#2Hiroaki Kanzaki (Chiba University)H-Index: 2
Last. Takayuki KondoH-Index: 6
view all 20 authors...
TPS595Background: CYT001 (CYTLIMIC Inc.) is a novel cancer vaccine involving artificial intelligence (AI)-designed shared-antigen peptides and optimal combined adjuvants that boost the cancer-immun...